|
Apixaban Clinical Trials
13 actively recruiting trials across 7 locations
No change since June 2026
Also known as: 1-(4methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4c]pyridine-3-carboxamide, AVK, B01A F02, C25H25N5O4, Eliquis +3 more
Pipeline
Early 1: 1Phase 2: 2Phase 3: 2Phase 4: 6
Top Sponsors
- Regeneron Pharmaceuticals2
- Ottawa Hospital Research Institute2
- Yale University1
- VA Office of Research and Development1
- University of Vermont Medical Center1
Indications
- Cancer7
- Heart Disease5
- Atrial Fibrillation4
- Venous Thromboembolism3
- Lung Cancer3
Other6 trials
Phase 4
Birmingham, Alabama1 trial
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
University of Alabama Hospital
Phase 3
Dothan, Alabama1 trial
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
SEC Clinical Research
Phase 2
Hialeah, Florida1 trial
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Bioresearch Partner- Hialeah Hospital
Phase 3
Miami, Florida1 trial
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
Miami VA Healthcare System, Miami, FL
Phase 4
Boston, Massachusetts1 trial
Apixaban in Thrombocytopenia
Beth Israel Deaconess Medical Center
Early 1
Syracuse, New York1 trial
Phase 4
Burlington, Vermont1 trial
Venous Thromboembolism Prevention in Outpatients With Glioma
University of Vermont Medical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.